Targeting the SphK1/S1P/S1PR1 axis with specific drugs can reduce tumor progression caused by key proinflammatory cytokines, macrophage infiltration, and obesity (Nagahashi et al., 2018). Here, SPHK1 is linked to obesity disorder.